Journal: Pharmaceutics

Article Title: Evaluation of an Affibody-Based Binder for Imaging of Immune Check-Point Molecule B7-H3

doi: 10.3390/pharmaceutics14091780

Figure Lengend Snippet: The sequence of amino acids in AC12-GGGC. For coupling 99m Tc to AC12, the sequence APK at C-terminus of parental AC12 Affibody molecule was replaced by the sequence GGGC.

Article Snippet: For the Radiolabelling, lyophilized Affibody molecule AC12-GGGC was weighted and dissolved in PBS (Corning, Glendale, AZ, USA) supplemented with 2 mM EDTA (Corning, Glendale, AZ, USA) to a final concentration of 2.0 mg/mL, taking the peptide content of 94.7% in consideration.

Techniques: Sequencing

Journal: Pharmaceutics

Article Title: Evaluation of an Affibody-Based Binder for Imaging of Immune Check-Point Molecule B7-H3

doi: 10.3390/pharmaceutics14091780

Figure Lengend Snippet: Characterization of anti-B7-H3 Affibody molecule. Reversed-phase HPLC chromatograms of non-labelled ( A ) AC12-GGGC and radiochromatogram of ( B ) [ 99m Tc]Tc-AC12-GGGC. The retention times (Rt) are expressed in minutes.

Article Snippet: For the Radiolabelling, lyophilized Affibody molecule AC12-GGGC was weighted and dissolved in PBS (Corning, Glendale, AZ, USA) supplemented with 2 mM EDTA (Corning, Glendale, AZ, USA) to a final concentration of 2.0 mg/mL, taking the peptide content of 94.7% in consideration.

Techniques:

Journal: Pharmaceutics

Article Title: Evaluation of an Affibody-Based Binder for Imaging of Immune Check-Point Molecule B7-H3

doi: 10.3390/pharmaceutics14091780

Figure Lengend Snippet: In vitro binding specificity of [ 99m Tc]Tc-AC12-GGGC on SKOV-3 and BT-474 cell lines. For the pre-saturation of B7-H3, a 200-fold molar excess of a non-labelled Affibody molecule was added before adding the labelled conjugate. Data are normalized to the average value of cell-associated radioactivity for non-blocked cells for each cell line. The data are presented as an average value from three samples ± SD.

Article Snippet: For the Radiolabelling, lyophilized Affibody molecule AC12-GGGC was weighted and dissolved in PBS (Corning, Glendale, AZ, USA) supplemented with 2 mM EDTA (Corning, Glendale, AZ, USA) to a final concentration of 2.0 mg/mL, taking the peptide content of 94.7% in consideration.

Techniques: In Vitro, Binding Assay, Radioactivity

Journal: Pharmaceutics

Article Title: Evaluation of an Affibody-Based Binder for Imaging of Immune Check-Point Molecule B7-H3

doi: 10.3390/pharmaceutics14091780

Figure Lengend Snippet: Apparent equilibrium dissociation constants (KD) for the interaction between [ 99m Tc]Tc-AC12-GGGC and SKOV-3 cells determined using an InteractionMap analysis of the LigandTracer sensorgrams.

Article Snippet: For the Radiolabelling, lyophilized Affibody molecule AC12-GGGC was weighted and dissolved in PBS (Corning, Glendale, AZ, USA) supplemented with 2 mM EDTA (Corning, Glendale, AZ, USA) to a final concentration of 2.0 mg/mL, taking the peptide content of 94.7% in consideration.

Techniques:

Journal: Pharmaceutics

Article Title: Evaluation of an Affibody-Based Binder for Imaging of Immune Check-Point Molecule B7-H3

doi: 10.3390/pharmaceutics14091780

Figure Lengend Snippet: LigandTracer sensorgram and InteractionMap of [ 99m Tc]Tc-AC12-GGGC binding to SKOV-3 cells. Input data were obtained from LigandTracer measurement of cell-bound activity during association of labelled conjugate to- and dissociation from SKOV-3 cells. Binding was measured at three different concentrations: 2, 6, and 18 nM. Measurement was performed in duplicates.

Article Snippet: For the Radiolabelling, lyophilized Affibody molecule AC12-GGGC was weighted and dissolved in PBS (Corning, Glendale, AZ, USA) supplemented with 2 mM EDTA (Corning, Glendale, AZ, USA) to a final concentration of 2.0 mg/mL, taking the peptide content of 94.7% in consideration.

Techniques: Binding Assay, Activity Assay

Journal: Pharmaceutics

Article Title: Evaluation of an Affibody-Based Binder for Imaging of Immune Check-Point Molecule B7-H3

doi: 10.3390/pharmaceutics14091780

Figure Lengend Snippet: Comparative biodistribution of [ 99m Tc]Tc-AC12-GGGC and [ 99m Tc]Tc-ZHER2:41071 Affibody molecules in different organs and tissues of female NMRI mice at 4 h after injection. 3 µg of labelled Affibody molecule (60 kBq, 100 µL in PBS) was injected into the tail vein. Data are expressed as %ID/g and are averages from four mice ± SD. The significance indicator (*) corresponds to p < 0.05 in.

Article Snippet: For the Radiolabelling, lyophilized Affibody molecule AC12-GGGC was weighted and dissolved in PBS (Corning, Glendale, AZ, USA) supplemented with 2 mM EDTA (Corning, Glendale, AZ, USA) to a final concentration of 2.0 mg/mL, taking the peptide content of 94.7% in consideration.

Techniques: Injection

Journal: Pharmaceutics

Article Title: Evaluation of an Affibody-Based Binder for Imaging of Immune Check-Point Molecule B7-H3

doi: 10.3390/pharmaceutics14091780

Figure Lengend Snippet: Uptake of [ 99m Tc]Tc-AC12-GGGC in SKOV-3 (B7-H3-positive) and Ramos (B7-H3-negative) xenografts at 4 h after injection. Data are expressed as %ID/g and are averages from four mice ± SD. p -value was obtained in unpaired t -test.

Article Snippet: For the Radiolabelling, lyophilized Affibody molecule AC12-GGGC was weighted and dissolved in PBS (Corning, Glendale, AZ, USA) supplemented with 2 mM EDTA (Corning, Glendale, AZ, USA) to a final concentration of 2.0 mg/mL, taking the peptide content of 94.7% in consideration.

Techniques: Injection

Journal: Pharmaceutics

Article Title: Evaluation of an Affibody-Based Binder for Imaging of Immune Check-Point Molecule B7-H3

doi: 10.3390/pharmaceutics14091780

Figure Lengend Snippet: Biodistribution and tumor-to-organ ratio of [ 99m Tc]Tc-AC12-GGGC in BALB/C nu/nu mice bearing SKOV-3 xenografts at 2 and 4 h after injection. Data are expressed as the percentage of administered activity (injected probe) per gram of tissue (%ID/g). The data are presented as the average ( n = 4) and SD.

Article Snippet: For the Radiolabelling, lyophilized Affibody molecule AC12-GGGC was weighted and dissolved in PBS (Corning, Glendale, AZ, USA) supplemented with 2 mM EDTA (Corning, Glendale, AZ, USA) to a final concentration of 2.0 mg/mL, taking the peptide content of 94.7% in consideration.

Techniques: Injection, Activity Assay

Journal: Pharmaceutics

Article Title: Evaluation of an Affibody-Based Binder for Imaging of Immune Check-Point Molecule B7-H3

doi: 10.3390/pharmaceutics14091780

Figure Lengend Snippet: Imaging of B7-H3-positive SKOV-3 xenograft (tumour in the left mouse) and B7-H3-negative Ramos xenograft (tumour in the right mouse) in BALB/C nu/nu mice using [ 99m Tc]Tc-AC12-GGGC 4 h after injection. 3 µg of labelled Affibody molecule (6 MBq, 100 µL in PBS) was injected into the tail vein. Arrows point at tumours.

Article Snippet: For the Radiolabelling, lyophilized Affibody molecule AC12-GGGC was weighted and dissolved in PBS (Corning, Glendale, AZ, USA) supplemented with 2 mM EDTA (Corning, Glendale, AZ, USA) to a final concentration of 2.0 mg/mL, taking the peptide content of 94.7% in consideration.

Techniques: Imaging, Injection

Journal: Frontiers in Immunology

Article Title: Development of Z HPV16E7 - granzyme B immunoaffitoxin: dual mechanisms targeting hpv16-positive cervical cancer through epithelial-mesenchymal transition inhibition and cell death

doi: 10.3389/fimmu.2025.1616715

Figure Lengend Snippet: Immune affinity of Z HPV16E7 -GrB for HPV16E7. (A) Prokaryotic expression and purification of Z HPV16E7 -GrB and the nontargeting control Z WT -GrB (wiled type affibody-conjugated GrB without affinity screening). Red arrows indicate the purified proteins. (B) Western blot confirming Z HPV16E7 -GrB binding via anti-His or anti-GrB mAbs. (C) Simulated 3D structure of Z HPV16E7 -GrB, with Z HPV16E7 as the HPV16E7-targeting affibody and a (G 4 S) 3 glycine-serine linker. (D) ELISA evaluation of Z HPV16E7 -GrB binding to HPV16E7. (E) ELISA binding titer of Z HPV16E7 -GrB to HPV16E7, with serial 1:5 dilutions and an OD 450 cutoff of 0.5 for invalid binding. (F) Laser confocal microscopy showed that after 24-hour incubation with 100 μg/mL of Z HPV16E7 -GrB, Z HPV16E7 , or Z WT -GrB, Z HPV16E7 -GrB colocalized with HPV16E7 in SiHa and CaSki (HPV16+) cells, but not in HeLa (HPV18+) or C33A (HPV-) cells. Scale bar = 100 μm.

Article Snippet: CTLs, Cytotoxic T Lymphocytes; EMT, Epithelial-Mesenchymal Transition; FBS, Fetal Bovine Serum; GrB, Granzyme B; GrB(O), Optimized Granzyme B; GrB(W), Wild-type Granzyme B; GSDME, Gasdermin E; GSDME-F, Gasdermin E - Gasdermin E - Full length; GSDME-N, Gasdermin E - N-terminal; HPV, Human Papillomavirus; LSD, Least Significant Difference; mAbs, Monoclonal Antibodies; NK, Natural Killer (cells); pRb, Retinoblastoma Protein; SD, Standard Deviations; Z HPV16E7 , HPV16E7-specific Affibody; Z HPV16E7 -GrB, HPV16E7-specific Affibody-Granzyme B Immunotoxin

Techniques: Expressing, Purification, Control, Western Blot, Binding Assay, Enzyme-linked Immunosorbent Assay, Confocal Microscopy, Incubation

Journal: Frontiers in Immunology

Article Title: Development of Z HPV16E7 - granzyme B immunoaffitoxin: dual mechanisms targeting hpv16-positive cervical cancer through epithelial-mesenchymal transition inhibition and cell death

doi: 10.3389/fimmu.2025.1616715

Figure Lengend Snippet: Analysis of cell growth inhibition affected by Z HPV16E7 -GrB. (A) Assessment of cervical cancer cell viability using a CellTiter-Lumi™ luminescence assay after 72-hour treatment with 100 μg/mL Z HPV16E7 -GrB, Z HPV16E7 , Z WT -GrB, or 50 μg/mL oxaliplatin. (B) Evaluation of cell damage induced by Z HPV16E7 -GrB through an LDH release assay following the same 72-hour treatment. Oxaliplatin was used as a positive control for cytotoxicity.

Article Snippet: CTLs, Cytotoxic T Lymphocytes; EMT, Epithelial-Mesenchymal Transition; FBS, Fetal Bovine Serum; GrB, Granzyme B; GrB(O), Optimized Granzyme B; GrB(W), Wild-type Granzyme B; GSDME, Gasdermin E; GSDME-F, Gasdermin E - Gasdermin E - Full length; GSDME-N, Gasdermin E - N-terminal; HPV, Human Papillomavirus; LSD, Least Significant Difference; mAbs, Monoclonal Antibodies; NK, Natural Killer (cells); pRb, Retinoblastoma Protein; SD, Standard Deviations; Z HPV16E7 , HPV16E7-specific Affibody; Z HPV16E7 -GrB, HPV16E7-specific Affibody-Granzyme B Immunotoxin

Techniques: Inhibition, Luminescence Assay, Lactate Dehydrogenase Assay, Positive Control

Journal: Frontiers in Immunology

Article Title: Development of Z HPV16E7 - granzyme B immunoaffitoxin: dual mechanisms targeting hpv16-positive cervical cancer through epithelial-mesenchymal transition inhibition and cell death

doi: 10.3389/fimmu.2025.1616715

Figure Lengend Snippet: Analysis of cell migration inhibition affected by Z HPV16E7 -GrB. (A, B) Transwell assay demonstrating the effect on cell migration. (C, D) Western blot analysis of EMT-related factors to evaluate the inhibition of epithelial-mesenchymal transition (EMT). These results were obtained after 24-hour treatment with 100 μg/mL of Z HPV16E7 -GrB, Z HPV16E7 , or Z WT -GrB.

Article Snippet: CTLs, Cytotoxic T Lymphocytes; EMT, Epithelial-Mesenchymal Transition; FBS, Fetal Bovine Serum; GrB, Granzyme B; GrB(O), Optimized Granzyme B; GrB(W), Wild-type Granzyme B; GSDME, Gasdermin E; GSDME-F, Gasdermin E - Gasdermin E - Full length; GSDME-N, Gasdermin E - N-terminal; HPV, Human Papillomavirus; LSD, Least Significant Difference; mAbs, Monoclonal Antibodies; NK, Natural Killer (cells); pRb, Retinoblastoma Protein; SD, Standard Deviations; Z HPV16E7 , HPV16E7-specific Affibody; Z HPV16E7 -GrB, HPV16E7-specific Affibody-Granzyme B Immunotoxin

Techniques: Migration, Inhibition, Transwell Assay, Western Blot

Journal: Frontiers in Immunology

Article Title: Development of Z HPV16E7 - granzyme B immunoaffitoxin: dual mechanisms targeting hpv16-positive cervical cancer through epithelial-mesenchymal transition inhibition and cell death

doi: 10.3389/fimmu.2025.1616715

Figure Lengend Snippet: Analysis of cell apoptosis affected by Z HPV16E7 -GrB. (A, B) TUNEL assay for apoptotic cell detection and quantitative analysis performed in SiHa, CaSki, HeLa, and C33A cells. Scale bar = 100 μm. (C, D) Flow cytometry with Annexin V/PI staining was used to assess apoptosis. (E, F) Western blot analysis of apoptosis-related proteins in SiHa and CaSki cells. All results were obtained from cells treated with 100 μg/mL Z HPV16E7 -GrB, Z HPV16E7 , or Z WT -GrB for 18 hours.

Article Snippet: CTLs, Cytotoxic T Lymphocytes; EMT, Epithelial-Mesenchymal Transition; FBS, Fetal Bovine Serum; GrB, Granzyme B; GrB(O), Optimized Granzyme B; GrB(W), Wild-type Granzyme B; GSDME, Gasdermin E; GSDME-F, Gasdermin E - Gasdermin E - Full length; GSDME-N, Gasdermin E - N-terminal; HPV, Human Papillomavirus; LSD, Least Significant Difference; mAbs, Monoclonal Antibodies; NK, Natural Killer (cells); pRb, Retinoblastoma Protein; SD, Standard Deviations; Z HPV16E7 , HPV16E7-specific Affibody; Z HPV16E7 -GrB, HPV16E7-specific Affibody-Granzyme B Immunotoxin

Techniques: TUNEL Assay, Flow Cytometry, Staining, Western Blot

Journal: Frontiers in Immunology

Article Title: Development of Z HPV16E7 - granzyme B immunoaffitoxin: dual mechanisms targeting hpv16-positive cervical cancer through epithelial-mesenchymal transition inhibition and cell death

doi: 10.3389/fimmu.2025.1616715

Figure Lengend Snippet: Analysis of cell pyroptosis induced by Z HPV16E7 -GrB. (A, B) SYTOX Green uptake in SiHa, CaSki, HeLa, and C33A cells, indicating membrane permeability changes. Scale bar = 100 μm. (C) Quantification of inflammatory factor release using ELISA kits. (D) Light microscopy observation of membrane blebbing in SiHa and CaSki cells, with red arrows highlighting swollen cells. (E, F) Western blot detection of the active GSDME-N fragment in SiHa and CaSki cells. All results were obtained from cells treated with 100 μg/mL Z HPV16E7 -GrB, Z HPV16E7 , or Z WT -GrB for 24 hours.

Article Snippet: CTLs, Cytotoxic T Lymphocytes; EMT, Epithelial-Mesenchymal Transition; FBS, Fetal Bovine Serum; GrB, Granzyme B; GrB(O), Optimized Granzyme B; GrB(W), Wild-type Granzyme B; GSDME, Gasdermin E; GSDME-F, Gasdermin E - Gasdermin E - Full length; GSDME-N, Gasdermin E - N-terminal; HPV, Human Papillomavirus; LSD, Least Significant Difference; mAbs, Monoclonal Antibodies; NK, Natural Killer (cells); pRb, Retinoblastoma Protein; SD, Standard Deviations; Z HPV16E7 , HPV16E7-specific Affibody; Z HPV16E7 -GrB, HPV16E7-specific Affibody-Granzyme B Immunotoxin

Techniques: Membrane, Permeability, Enzyme-linked Immunosorbent Assay, Light Microscopy, Western Blot

Journal: Frontiers in Immunology

Article Title: Development of Z HPV16E7 - granzyme B immunoaffitoxin: dual mechanisms targeting hpv16-positive cervical cancer through epithelial-mesenchymal transition inhibition and cell death

doi: 10.3389/fimmu.2025.1616715

Figure Lengend Snippet: Pyroptosis analysis following caspase-3 knockdown. (A) Verification of caspase-3 knockdown in SiHa cells using siRNA. (B, C) Detection of cleaved GSDME in SiHa cells after caspase-3 knockdown. (D, E) Pyroptosis of SiHa cells after caspase-3 knockdown, treated with 100 μg/mL Z HPV16E7 -GrB, observed by uptake of the membrane-impermeable dye SYTOX Green. Scale bar = 100 μm. (F) Quantification of inflammatory factor release in SiHa cells under the same treatment conditions as in (D, E) .

Article Snippet: CTLs, Cytotoxic T Lymphocytes; EMT, Epithelial-Mesenchymal Transition; FBS, Fetal Bovine Serum; GrB, Granzyme B; GrB(O), Optimized Granzyme B; GrB(W), Wild-type Granzyme B; GSDME, Gasdermin E; GSDME-F, Gasdermin E - Gasdermin E - Full length; GSDME-N, Gasdermin E - N-terminal; HPV, Human Papillomavirus; LSD, Least Significant Difference; mAbs, Monoclonal Antibodies; NK, Natural Killer (cells); pRb, Retinoblastoma Protein; SD, Standard Deviations; Z HPV16E7 , HPV16E7-specific Affibody; Z HPV16E7 -GrB, HPV16E7-specific Affibody-Granzyme B Immunotoxin

Techniques: Knockdown, Membrane

Journal: Frontiers in Immunology

Article Title: Development of Z HPV16E7 - granzyme B immunoaffitoxin: dual mechanisms targeting hpv16-positive cervical cancer through epithelial-mesenchymal transition inhibition and cell death

doi: 10.3389/fimmu.2025.1616715

Figure Lengend Snippet: Z HPV16E7 -GrB directly cleaves GSDME. (A) Expression of GSDME-FLAG in SiHa cells, detected by anti-FLAG antibody. (B) Purification of recombinant GSDME-FLAG (from A) via affinity chromatography. (C) Western blot analysis of purified GSDME-FLAG using anti-GSDME antibody. (D) For the in vitro cleavage assay, purified FLAG-GSDME (100 μg) was incubated with equimolar amounts (100 μg) of Z HPV16E7 -GrB, Z WT -GrB, or Z HPV16E7 in reaction buffer at 37°C for 1 hour. GSDME cleavage was then analyzed by Western blot using anti-GSDME antibody.

Article Snippet: CTLs, Cytotoxic T Lymphocytes; EMT, Epithelial-Mesenchymal Transition; FBS, Fetal Bovine Serum; GrB, Granzyme B; GrB(O), Optimized Granzyme B; GrB(W), Wild-type Granzyme B; GSDME, Gasdermin E; GSDME-F, Gasdermin E - Gasdermin E - Full length; GSDME-N, Gasdermin E - N-terminal; HPV, Human Papillomavirus; LSD, Least Significant Difference; mAbs, Monoclonal Antibodies; NK, Natural Killer (cells); pRb, Retinoblastoma Protein; SD, Standard Deviations; Z HPV16E7 , HPV16E7-specific Affibody; Z HPV16E7 -GrB, HPV16E7-specific Affibody-Granzyme B Immunotoxin

Techniques: Expressing, Purification, Recombinant, Affinity Chromatography, Western Blot, In Vitro, Cleavage Assay, Incubation

Journal: Frontiers in Immunology

Article Title: Development of Z HPV16E7 - granzyme B immunoaffitoxin: dual mechanisms targeting hpv16-positive cervical cancer through epithelial-mesenchymal transition inhibition and cell death

doi: 10.3389/fimmu.2025.1616715

Figure Lengend Snippet: Mechanistic diagram of Z HPV16E7 -GrB action in HPV16-positive cervical cancer cells. Z HPV16E7 -GrB consists of Z HPV16E7 (targeting HPV16E7), a flexible peptide linker, and GrB. Z HPV16E7 inhibits the growth of HPV16-positive cervical cancer cells and suppresses EMT, as evidenced by reduced expression of Vimentin and Snail, increased expression of E-cadherin, and decreased expression of N-cadherin. GrB exerts its function by inducing two forms of programmed cell death: apoptosis and pyroptosis. It induces apoptosis via caspase-3 and caspase-8 activation, accompanied by an increase in the pro-apoptotic factor Bax and a significant reduction in the anti-apoptotic factor Bcl-2. Additionally, GrB triggers pyroptosis through direct cleavage of GSDME, independent of caspase-3 activity, leading to membrane rupture and the release of proinflammatory cytokines, including IL-18, IL-1β, and HMGB1.

Article Snippet: CTLs, Cytotoxic T Lymphocytes; EMT, Epithelial-Mesenchymal Transition; FBS, Fetal Bovine Serum; GrB, Granzyme B; GrB(O), Optimized Granzyme B; GrB(W), Wild-type Granzyme B; GSDME, Gasdermin E; GSDME-F, Gasdermin E - Gasdermin E - Full length; GSDME-N, Gasdermin E - N-terminal; HPV, Human Papillomavirus; LSD, Least Significant Difference; mAbs, Monoclonal Antibodies; NK, Natural Killer (cells); pRb, Retinoblastoma Protein; SD, Standard Deviations; Z HPV16E7 , HPV16E7-specific Affibody; Z HPV16E7 -GrB, HPV16E7-specific Affibody-Granzyme B Immunotoxin

Techniques: Expressing, Activation Assay, Activity Assay, Membrane

Journal: EJNMMI Radiopharmacy and Chemistry

Article Title: A novel 18 F-labelled tetrazine ester prosthetic group for improved radiolabelling and in vivo stability of proteins and peptides

doi: 10.1186/s41181-026-00430-6

Figure Lengend Snippet: Stability of [ 18 F]TzE2-Z09591, [ 18 F]TzAm-Z09591 and [ 18 F]TzE-Z09591 in PBS formulation over time (shelflife) ( A ) and after 90 min incubation in human plasma ( B ). One star (*) indicates p < 0.05, two stars (**) indicate p < 0.01 and three stars (***) indicate p < 0.001 using ANOVA for comparison between groups

Article Snippet: The Affibody molecule Z09591, which is a small 58 amino acid protein with high affinity for human and murine Platelet Derived Growth Factor Receptor β (PDGFRβ), demonstrated excellent receptor targeting and stability in vitro and in vivo.

Techniques: Formulation, Incubation, Clinical Proteomics, Comparison

Journal: EJNMMI Radiopharmacy and Chemistry

Article Title: A novel 18 F-labelled tetrazine ester prosthetic group for improved radiolabelling and in vivo stability of proteins and peptides

doi: 10.1186/s41181-026-00430-6

Figure Lengend Snippet: Binding of [ 18 F]TzE2-Z09591, [ 18 F]TzAm-Z09591 and [ 18 F]TzE-Z09591 to frozen sections of PDGFRβ overexpressing U87 xenografts by an in vitro autoradiography assay. Quantification of binding signal as percentage of total binding ( A ). Representative autoradiograms for each of the tracers, both total binding (5 nM, top row panels), and after pre-blocking with 2 µM unlabeled Z09591 (bottom row panels) ( B )

Article Snippet: The Affibody molecule Z09591, which is a small 58 amino acid protein with high affinity for human and murine Platelet Derived Growth Factor Receptor β (PDGFRβ), demonstrated excellent receptor targeting and stability in vitro and in vivo.

Techniques: Binding Assay, In Vitro, Autoradiography, Blocking Assay

Journal: EJNMMI Radiopharmacy and Chemistry

Article Title: A novel 18 F-labelled tetrazine ester prosthetic group for improved radiolabelling and in vivo stability of proteins and peptides

doi: 10.1186/s41181-026-00430-6

Figure Lengend Snippet: In vivo biodistribution over time of [ 18 F]TzE2-Z09591 ( A ), [ 18 F]TzAm-Z09591 ( B ) and [ 18 F]TzE-Z09591 ( C ) in female wt Balb/c mice. Biodistribution was assessed by post-mortem organ distribution measurement by gamma counter, for up to 120 min after intravenous administration of each tracer. A direct comparison with more repeats (n = 4–6) in immunodeficient nu/nu Balb/c mice was compared at 60 min post-injection ( D ). A star (*) indicates difference compared to uptake of [ 18 F]TzE2-Z09591

Article Snippet: The Affibody molecule Z09591, which is a small 58 amino acid protein with high affinity for human and murine Platelet Derived Growth Factor Receptor β (PDGFRβ), demonstrated excellent receptor targeting and stability in vitro and in vivo.

Techniques: In Vivo, Comparison, Injection